LIVING WITH IT WORKING WITH IT TREATING IT
InTech is committed to disseminating all published research without restricting access to anyone or anywhere in the world. Our fundamental vision is to allow all scientific communities, academia and professionals in scientific domains to access relevant research free of any charges. This is why, since 2004, InTech has actively contributed to easing the fundamental problem of limited access to knowledge offering scientific resources at no cost to scientific communities worldwide.
Furthermore, we strive to give all researchers the equal opportunity to share their knowledge and for their work to have an impact.
This is why we are immensely proud of the variety of our authors' and editors' geographical origin. We have worked with 91,942 authors and editors from 3,143 institutions and 152 countries.
Welcome to the Pathology Education Informational Resource (PEIR) Digital Library, a multidisciplinary public access image database for use in medical education
If you wish to sign up to the cTOC, you may do so here and click on “subscribe to new volume alerts”. Also there is a guiding article on how to write a case report, see here.
Welcome to the Elsevier Respiratory Webcasts Platform. These webcasts provide clinicians with data presented at two satellite symposia, at the 2015 European Respiratory Society (ERS) International Congress, on Immunoglobulin E (IgE)-mediated asthma, and new paradigms for chronic obstructive pulmonary disease (COPD).
Thousands of accumulated protocols useful for a wide range of scientific experimentation, including fungi.
Businesses and research organisations can apply to funding competitions to help them develop their innovations.
All of the current and forthcoming funding competitions run by Innovate UK are published here.
You can apply for funding to test the feasibility of your idea, research and develop it and demonstrate it in a prototype.
Innovate UK funding competitions cover the following industry sectors:
We also have an open programme that is not sector based.
We also run funding competitions in partnership with government, other agencies and bodies.
Browse, register and apply for our current competitions.
This special series of commentaries, interviews, and slideshows is part of a collaboration between CDC and Medscape. This content is designed to deliver CDC's authoritative guidance directly to Medscape's physicians, nurses, pharmacists, and other healthcare professionals.
**Requires membership of Medscape to view, but membership is free of charge.
FungiMICs is intended as an easy-to-use information source for physicians working in the field of fungal infections. The app aims to provide MIC data and associated clinical breakpoints and epidemiological cut-off (ECOFF) values for different organism–drug interactions, in an intuitive and practical format.
Fungal diseases can affect anyone. Learning about them can help you and your doctor recognize the symptoms of a fungal disease early and may help prevent serious complications.
Fungal diseases are often caused by fungi that are common in the environment. Most fungi are not dangerous, but some types can be harmful to health.
Mild fungal skin diseases can look like a rash and are very common. Fungal diseases in the lungs are often similar to other illnesses such as the flu or tuberculosis. Some fungal diseases like fungal meningitis and bloodstream infections are less common than skin and lung infections but can be deadly.
All good medical practice follows from an accurate and timely diagnosis. The approach that LIFE takes with respect to improving patient outcomes is a holistic one, but tempered by the realities of each country and region. In some countries, certain fungal infections are common and the emphasis should be on these, and others are rare and are therefore secondary problems to be dealt with. Diagnosis is the cornerstone of good medicine and clinical care.
LIFE aims to reach all medical practitioners and other healthcare professionals who see and treat fungal infections and those who contribute to the diagnosis such as laboratory workers and radiologists. Clinical expertise, and access to diagnostic facilities are all critical to improving outcomes. Likewise access to antifungal therapies is absolutely necessary for almost all serious fungal infections. The website is also provided in Spanish to facilitate international reach. An online course on microscopy and histology for fungal disease will be launched in 2016. Public awareness is also important specifically for some diseases such as SAFS and both skin and mucosal fungal infections.
Rare Disease Day takes place on the last day of February each year.
The main objective of Rare Disease Day is to raise awareness amongst the general public and decision-makers about rare diseases and their impact on patients' lives.
The campaign targets primarily the general public and also seeks to raise awareness amongst policy makers, public authorities, industry representatives, researchers, health professionals and anyone who has a genuine interest in rare diseases.
Since Rare Disease Day was first launched by EURORDIS and its Council of National Alliances in 2008, thousands of events have taken place throughout the world reaching hundreds of thousands of people and resulting in a great deal of media coverage.
The political momentum resulting from Rare Disease Day also serves advocacy purposes. It has notably contributed to the advancement of national plans and policies for rare diseases in a number of countries.
The campaign started as a European event and has progressively become a world phenomenon, with the USA joining in 2009 and participation in over 80 countries throughout the world in 2015. Hundreds of cities continue to take part in Rare Disease Day and we hope even more will join in 2016. Some countries have decided to raise rare disease awareness further, for example, Spain declared 2013 as the National Year for Rare Diseases.
On rarediseaseday.org you can find information about the thousands of events happening around the world to build awareness for people living with a rare disease and their families. If you are planning an event, register your event details on our Post your Event page to get your event listed on the site.
Fungal diseases are neglected worldwide by public health authorities. Globally, over 300 million people of all ages suffer from a serious fungal infection every year. Of these over 1.66 million people are estimated to die, in comparison deaths from malaria and tuberculosis are 0.6 and 1.54 million respectively. Most serious fungal infections are ‘hidden’ because of other health problems such as - AIDS, cancer, transplantation, or asthma. Some are injury related such as fungal eye infections in farmers, How do you feed your children when your blindness stops you from working? Tens of thousands lose their eyesight every year from fungal keratitis. It is rarely diagnosed and treated. Serious fungal infections require specialized testing (view).
Alongside our Country Ambassadors, GAFFI has estimated the world's burden of fungal disease, described in a recent plenary lecture in Montreal by GAFFI's President(View). Antifungal drug availability is a major limitation to improved outcome, link.
GAFFI hosted a global fungal infection forum in Seattle and is calling for 95-95 by 2025, the objective: 95% of patients with serious fungal infections are diagnosed and treated.
FungiDB belongs to the EuPathDB family of databases and is an integrated genomic and functional genomic database for the kingdom Fungi. FungiDB was first released in early 2011 as a collaborative project between EuPathDB and the group of Jason Stajich (University of California, Riverside). At the end of 2015, FungiDB was integrated into the EuPathDB bioinformatic resource center - see this news item for additional information. For a list of the data integrated into FungiDB today and the related publications please see Data Sets.
FungiDB integrates whole genome sequence and annotation and also includes experimental and environmental isolate sequence data. The database includes comparative genomics, analysis of gene expression, and supplemental bioinformatics analyses and a web interface for data-mining.
Methods for susceptibility testing of Candida and Aspergillus are developed and validated by the EUCAST subcommittee on AFST.
New and revised documents open for consultation will until accepted be published in the EUCAST News section together with all other consultations from EUCAST.
Information on subcommittee organisation and members are available on the webpage describing the Organisation of EUCAST.
Information for industry aiming to bring agents to EUCAST for review and revision of breakpoints or a new agent to EMA for registration is available at Information for industry.
Development of new methods and validation and calibration of existing methods is performed at the EUCAST Development Laboratory for AFST:The EUCAST Development Laboratory for Antifungal Susceptibility Testing
with the help of
The EUCAST AFST Network Laboratories
Chairman Maiken Cavling Arendrup (maiken.c.arendrup[at]escmid.org)
Scientific Secretary Susan J Howard (susan.howard[at]escmid.org)
Clinical Data Coordinator Joseph Meletiadis (joseph.meletiadis[at]escmid.org)
EUCAST Development Laboratory for fungi
c/o Unit of Mycology
Dept. Microbiology & Infection Control
Statens Serum Institut, Building 211
Phone: +45 3268 3223 or +45 3268 3116
Email: [email protected]
The EUCAST Development Laboratories (EDL) are responsible for antimicrobial susceptibility testing of bacteria and antimicrobial susceptibility testing of fungi. Both laboratories are prepared to offer advice and provide trouble shooting in their respective field.
EUCAST Development Laboratory (EDL) for bacteria
c/o Erika Matuschek
SE-351 85 Växjö
EUCAST Development Laboratory (EDL) for fungi
c/o Maiken Cavling Arendrup
Unit for Mycology, building 211, 1st floor
Statens Serum Institute
DK-2300 Copenhagen S
The International Resource for Infection Control (iNRIC) brings together the best available on-line evidence-based, quality-tagged resources on infection prevention and control. A key benefit of iNRIC is the reviewer's assessments attached to documents within the library.
Whether you are a patient, a carer or just interested in your health, Pfizerlife aims to help you make more informed decisions about how you can live your life in the best possible health.
There are lots of links here to help you with managing your health and using the NHS more effectively.
If you have ever had athlete's foot or a yeast infection, you can blame a fungus. A fungus is a primitive organism. Mushrooms, mold and mildew are examples. Fungi live in air, in soil, on plants and in water. Some live in the human body. Only about half of all types of fungi are harmful.
Some fungi reproduce through tiny spores in the air. You can inhale the spores or they can land on you. As a result, fungal infections often start in the lungs or on the skin. You are more likely to get a fungal infection if you have a weakened immune system or take antibiotics.
Fungi can be difficult to kill. For skin and nail infections, you can apply medicine directly to the infected area. Oral antifungal medicines are also available for serious infections.
In the current context we can only give an extremely brief introduction to the basic notions of molecular biology. An overview can be found in any modern textbook on biology, biochemistry or molecular biology (e.g. [ABL89], [Str88]). [Goa86] is a short review of computational methods in biological sequence analysis and recently several books summarizing problems and methods have been published ([Doo86], [Hei87], [Les88]).
Some use “microbiome” to mean all the microbes in a community. We and others use it to mean the full collection of genes of all the microbes in a community. The human microbiome (all of our microbes’ genes) can be considered a counterpart to the human genome (all of our genes). The genes in our microbiome outnumber the genes in our genome by about 100 to 1.
Microbes are everywhere: in the soil, in the water, and even in our bodies. That's right! Microbes cover every surface of our bodies, both inside and out. These microscopic life forms represent thousands of species, and they outnumber our own cells by about 10 to 1.
Aspergillus is one member of our microbiome community - even for people without aspergillosis!
Some scientists view our resident microbes as a newly discovered and largely unexplored organ, with many functions that are essential for life. Explore to learn more about the human microbiome.
The International Resource for Infection Control (iNRIC) brings together the best available on-line evidence-based, quality-tagged resources on infection prevention and control. Training courses listed are mainly UK-based
A new online version of the 4th edition is now available!
It will allow fast and very comfortable search through the entire Atlas text. The engine is fully equipped for title as well as for general search. Items are strongly linked, enabling direct use of the electronic version as a benchtool for identification and comparison. Text boxes with concise definitions appear, explaining all terminology while reading. The fourth edition will contain nearly 600 clinically relevant species, following all major developments in fungal diagnostics. Regular updates of the Atlas are planned, which should include numerous references to case reports, as well as expanded data on antifungals.
Our most recent newsletters (since August 2018) can be found here.
An archive of our older newsletters (dating back to 2006) can be found here.